Max Robotics — Global Service Robot Directory + US Certification

About

Wolfgang Lilleby is a leading clinical researcher in prostate cancer, with a career dedicated to improving both the curative outcomes and the quality of life for patients. His work sits at the intersection of advanced immunotherapy and rigorous survivorship science. Dr. Lilleby’s major contributions include pioneering a first-in-man Phase I/II study of an adjuvant dendritic cell (DC) vaccine for high-risk prostate cancer patients after radical prostatectomy, a personalized immunotherapy approach aimed at reducing biochemical relapse (cited 30 times). He is equally renowned for his methodological innovations in measuring adverse effects, developing the “Proportions of patients regaining 90% of baseline function score” (PBS-90) method to precisely quantify recovery of sexual and urinary function after surgery or radiotherapy. His research has also critically examined clinician compliance with treatment guidelines at comprehensive cancer centers, revealing real-world decision-making challenges. With a portfolio of highly cited papers, Lilleby’s impact is defined by his dual focus: pushing the boundaries of immune-based adjuvant therapy while simultaneously refining how we measure and mitigate the “bother” of treatment side effects, directly informing patient counseling and clinical practice.